EB-BH2024-2
/ Essen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 15, 2024
BAH242: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1/2 | N=75 | Recruiting | Sponsor: Essen Biotech | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Jul 2024
CAR T-Cell Therapy • Enrollment open • Trial initiation date • ANCA Vasculitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Myositis • Nephrology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis
May 31, 2024
BAH247: Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Essen Biotech | Not yet recruiting ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Sjogren's Syndrome • Systemic Lupus Erythematosus
May 24, 2024
BAH247: Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1/2 | N=60 | Not yet recruiting | Sponsor: Essen Biotech
New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Sjogren's Syndrome • Systemic Lupus Erythematosus
1 to 3
Of
3
Go to page
1